In trials, the antipsychotic drug brexpiprazole (Rexulti) failed to provide a clinically meaningful benefit and increased the risk of death. Yet the US Food and Drug Administration (FDA) has fast ...

With an FDA advisory committee recommendation in hand, Lundbeck and Otsuka’s Rexulti is one step closer to locking down a new indication in Alzheimer’s disease related agitation. In a 9-1 vote on ...

Otsuka Pharmaceutical Co. Ltd. and Lundbeck LLC announced on May 10 that their D2 dopamine receptor agonist, brexpiprazole, aka Rexulti, had been approved by the U.S. Food and Drug Administration for ...

"I was very impressed with the sponsor's data and I also thought the agency and sponsor worked really well together to address a very, very difficult area with such a great need," said PDAC ...

Consuming soft drinks may contribute to major depressive disorder (MDD) through gut microbiota alterations, with stronger effects seen among women, a German study suggested. (JAMA Psychiatry) Nearly ...

Alembic has received permission from the Food and Drug Administration for brexpiprazole tablets, which is the generic of Otsuka’s Rexulti. Brexpiprazole is an atypical antipsychotic used as an ...

Please provide your email address to receive an email when new articles are posted on . Approval makes Rexulti the lone treatment approved for agitation associated with Alzheimer’s dementia. Two FDA ...

The Food and Drug Administration has given Otsuka and Lundbeck approval for Rexulti (brexpiprazole) oral tablets for the treatment of agitation associated with dementia due to Alzheimer's disease.

Please provide your email address to receive an email when new articles are posted on . The FDA has accepted a supplemental new drug application from Otsuka and Lundbeck for Rexulti in combination ...